Ethyl-EPA Treatment of Prodromal Patients

This study is ongoing, but not recruiting participants.

First Received: March 6, 2008 Last Updated: March 12, 2008 History of Changes

Sponsored by:	Yale University
Information provided by:	Yale University
ClinicalTrials.gov Identifier:	NCT00634361

Purpose

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Condition	Intervention	Phase
Schizophrenia Prodrome	Drug: ethyl-eicosapentaenoic acid	Phase II Phase III

Study Type:	Interventional
Study Design:	Treatment, Open Label, Single Group Assignment
Official Title:	Ethyl-EPA Treatment of Prodromal Patients

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia

Drug Information available for: Docosahexaenoic acids Eicosapentaenoic acid

Further study details as provided by Yale University:

Primary Outcome Measures:

conversion to psychosis [ Time Frame: one year ] [ Designated as safety issue: No ]

Enrollment:	6
Study Start Date:	September 2001
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Experimental	Drug: ethyl-eicosapentaenoic acid 2 mg per day

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00634361

Sponsors and Collaborators

Yale University

Investigators

Principal Investigator:

Scott W Woods, MD

Yale University

More Information

No publications provided

Responsible Party:	Yale University School of Medicine ( Scott W. Woods, M.D. )
Study ID Numbers:	LA01.03.0011
Study First Received:	March 6, 2008
Last Updated:	March 12, 2008
ClinicalTrials.gov Identifier:	NCT00634361 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Schizophrenia
Mental Disorders
Omega 3 Fatty Acid
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Schizophrenia
Mental Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on September 10, 2009